💊 Wegovy Wars: Novo vs. The Compounders

How compounding pharmacies, legal gray zones, and regulatory silence are testing the limits of biotech defensibility - with Novo Nordisk at the center.

🔑 Executive Summary

Novo Nordisk’s (NVO) Wegovy franchise is booming - up 67% YoY, turbocharged by GLP-1 hype, expanding label approvals, and global demand. But the real war has just begun.

Rival compounded GLP-1s are flooding the market, threatening to undercut pricing, erode margins, and bypass traditional pharma IP barriers. Novo’s pristine growth story is now entering the courtroom, the regulatory arena, and the profit margin spreadsheet - all at once.

This is no longer just about diabetes and weight loss. It’s about the future of pharma defensibility.

---

🌍 Macro Lens

• GLP-1s are the first true secular growth engine in pharma since biologics.

• Obesity is now recognized as a global health crisis with economic ramifications → GLP-1 access = fiscal health policy.

• Pricing pressure is macro: U.S. drug inflation, employer cost sharing, and CMS negotiation mandates are all converging.

• Compounding boom = regulatory arbitrage: a byproduct of a fragmented U.S. healthcare system + weak FDA enforcement.

• Courts are now frontline actors in determining how much pricing power IP actually provides in the era of biological copycats.

---

💉 Market Players at War

1. Novo Nordisk (NVO)

• 🧱 Dominant incumbent with the #1 global GLP-1 franchise: Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral semaglutide).

• 📈 Q2 2025 GLP-1 growth: +67% YoY globally; Wegovy alone grew 67%, with U.S. volumes driving most of the surge.

• 🌍 U.S. GLP-1 sales up 55% YoY; international markets up 39%.

• 💰 Gross margin steady at +83.1%, but company warned of compounding risks and pricing pressure.

• 🚨 CEO reiterated concerns about operating cost pressure from compounded competition and uncertain regulatory environment.

• 🔒 Suing compounders, lobbying FDA and state boards, pursuing international IP enforcement.

2. Eli Lilly (LLY)

• ⚔️ Primary rival via Mounjaro (T2D) and Zepbound (obesity).

• 🚀 Gaining market share as demand outpaces Novo’s supply chain in some regions.

• 🧠 Advancing next-gen GLP-1 combo drugs and Alzheimer’s trials; also pushing oral delivery innovation.

• 📊 Hasn’t yet seen the same level of compounded pressure as Novo - benefiting from the shadow market being Ozempic-centric.

3. The Compounders (e.g., Empower, Wells Pharmacy)

• 🧪 Exploiting FDA “shortage list” carveouts to legally offer off-label semaglutide.

• 💸 Price points often 30-50% lower than branded GLP-1s - with limited oversight.

• ⚖️ Facing escalating legal threats - Novo filed multiple new lawsuits in July 2025.

• 🧬 Often using salt-based or non-sterile formulations that challenge IP interpretation.

4. Telehealth Disruptors (Ro, Hims, PlushCare)

• 📲 Packaging compounded GLP-1s into slick subscription offerings with $199/mo pricing tiers.

• 🎯 Targeting younger, wellness-focused demographics with aggressive DTC marketing.

• 🔌 Acting as distribution multipliers for compounders - not FDA-regulated drug sellers themselves.

• 🧨 Could become regulatory flashpoints if adverse events or counterfeits emerge.

---